BioTrinity 2009 Sponsors and Project Partners

Gold Sponsors

MEPC Milton Park
MEPC is a leading developer of sustainable business communities. It owns more than 12 million sq ft of business space and lets to over 850 occupiers across the country. Milton Park is one of MEPC’s sustainable business communities and is located about 12 miles south of Oxford just off the A34 dual carriageway. Milton Park is a leading biotech cluster in the UK with over 400,000 sq ft of existing laboratory space and plans for significant further expansion - over 50,000 sq ft Innovation Centre and Graduation Space plus and a new Bioscience Campus of 80,000 sq ft.
The exciting mix of start-ups through to world class PLC’s ensures a dynamic and vibrant environment ideal for cutting edge R&D activities. This critical mass of like-minded companies creates a hub for further innovation and collaboration. MEPC Milton Park is committed to providing the property skills and expertise required at all stages of a business’ development.

Silver Sponsors

Shire
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

(OSI) Prosidion
(OSI) Prosidion is the name used in the South-East for the UK subsiduary of OSI Pharmaceuticals.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. Our strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth.

OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. Our Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes.

Our Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs.

Our goal is to pave the way for the future of oncology, diabetes and obesity treatments. We believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Merck Sharp & Dohme
Merck & Co., Inc., USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life.
At Merck, our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2005 were $22 billion and Merck continues to invest heavily in research and development.

UK Trade & Investment
UK Trade & Investment is a UK government organisation. We help UK companies do business abroad - and we help overseas companies do business in the UK.
The Biotech and Pharmaceutical International Sector Team has sector–specfic specialists waiting to help you in internationalising your business. With over 75 years of accumulated high-end corporate experience behind them. Our specialists have experience in helping BioPharma companies internationally in the markets of Japan, Korea, India and China as well as Europe and the USA.

Genzyme UK
Genzyme UK is part of one of the world's leading biotechnology companies, dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown into a diversified enterprise with more than 8,000 employees in locations spanning the globe and 2005 revenues of $2.7 billion. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. In the UK, Genzyme has a long history, beginning with the acquisition of UK-based speciality pharmaceutical firms in 1981. Genzyme is now a significant presence in the UK biotechnology industry, employing around 500 people.

Bronze Sponsors

James Cowper Accountants and Advisors
As a leading firm of accountants and business advisors, James Cowper's aim is simple - to draw on our experience and expertise to help you achieve eral success. Fresh thinking, diverse skills and a sharp eye for the broader pictures mean that together, we can really make things happen.

What sets James Cowper apart from the rest of the UK’s top accountants and business advisers? Professionalism, flexibility, but above all, passion. Our clients? As varied as our skills, each advised according to their specific needs. Each equally important to us.

We’ve decades of experience behind us but our knowledge is ‘in the now’ and our vision trained on the future. Whatever your requirement – be it starting out with a new business venture, flotation or tax planning for the private client – we have the breadth of expertise to help you achieve real success. OBN chose James Cowper as its accountancy firm because of its expertise with technology-based businesses.

Fisher Scientific
As a world-leading supplier of laboratory chemicals, consumables and equipment to the scientific community, Fisher Scientific is proud to be a key sponsor of OBN. Fisher Scientific realise that it’s future lies within the bioscience sector and indeed, building relationships with networks such as OBN. Fisher Scientific, therefore, recognises the need to support such important initiatives as BioTrinity. As part of Fisher Scientific’s strategy, it looks to support the members of the OBN community with a wide range of products; specific offers and services designed for scientists and researchers within the bioscience areas. Fisher Scientific is part of the Thermo Fisher Group, the world’s largest manufacturer and supplier of products to the scientific community.

Tepnel Research Products & Services

Tepnel offers an established and comprehensive range of laboratory testing services supporting small and large molecule analysis from early discovery and pre-clinical to first in man through to phase IV clinical support and post-marketing surveillance.

Bioanalytical services. Tepnel offers rapid analysis of samples employing techniques including HPLC, UPLC, GC, LC/MSMS, ion chromatography and various immunological techniques. It also specialises in the design of assays for the identification or quantification of novel biomarkers.

Genetic analysis services. Tepnel provides whole project solutions including DNA & RNA extraction from blood, cells and tissues (including FFPE), genome-wide to customised, CNV, SNP genotyping, gene expression and epigenetic analysis on Illumina and Taqman platforms, and bioinformatic support at project design and data analysis.

Tepnel also offers regulatory services and analytical solutions for small and large molecule products in method development and validation, biomanufacturing, batch release, microbiology and stability testing, under inspection and approval of the MHRA and FDA.

BioCentury
Now in its 15th Year, BioCentury is recognized as the ESSENTIAL provider of independent, informed business intelligence that regularly affects decisions made by bio-industry leaders and investors throughout the world.

BioCentury's mission is to provide value-added information and analysis for biotech and pharma companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of biopharmaceutical ventures.

Our breadth of coverage includes corporate strategy, partnering, emerging technology, clinical data, public policy and the financing markets.

Giles Insurance
Insurance solutions for the lifescience sector
Giles Insurance Brokers Ltd are specialists in the lifescience sector acting for more than 200 clients in the UK and overseas, from university spin-outs to main market listed companies, including companies involved in the research, development and supply of pharmaceutical and medtech products, CROs and related service providers.
We are proud to be sponsors of both OBN and the BIA.

Specialist areas

We offer a range of specialist insurance products and services, including:

• Global clinical trials
• Pharmaceutical and medical product liability
• Bio-medical errors & omissions / professional indemnity
• Medical malpractice
• Intellectual property litigation and protection
• R&D and supply chain protection
• Marine and goods in transit
• Directors & Officers indemnity

Saltigo GmbH Saltigo’s Fluorine Team has more than 40 years of expertise in fluorine chemistry. Our technology and know-how supports the activities of our customers in life science R&D. We provide new fluorinated building blocks and utilise innovative methods for selective introduction of fluorine to support the challenge of drug development from discovery to preclinical programs. The Fluorine Team is embedded within Saltigo’s Business Line Pharma. Saltigo provides custom synthesis and manufacturing service for pharmaceuticals from pre-clinical to commercial manufacture.

The Fluorine Team service portfolio comprises:

synthesis of non-commercial fluorinated building blocks
immediate delivery of stock items
generation of novel substance-classes
new synthesis strategies for key-intermediates

We have access to more than 4,500 fluorinated building blocks on stock and approx. 24,000 virtual fluorinated synthons enable the best possible service for our customers.

Manches LLP

Manches LLP is a leading law firm with offices in Oxford and London. The Firm offers the full range of company and commercial legal services with a particular emphasis on the life science sector. Of the eight specialist pharmaceutical and biotechnology lawyers listed by Legal 500 for the South East England, three are partners at Manches. The firm has the largest specialist group of lawyers in the South East (excluding London). Typical services to clients involve:
• Establishment, seed funding and funding rounds
• Listing or trade sale
• Collaborative research agreements
• Use of project results and background technology
• Setting up spin-outs and joint ventures
• Securing IPR
• In-licensing and out-licensing
• Co-development and co-marketing
• Clinical manufacturing, clinical supply and clinical trials
• Distribution and supply
• Domestic and foreign litigation
• International arbitration
• Human Resources
• Property requirements
• IT infrastructure and acquisition

PharmaVentures
PharmaVentures are a specialist advisory firm serving the global pharmaceutical industry and a world leader in deals and alliances.

PharmaVentures offer a comprehensive range of strategic and transaction services, and our unrivalled bank of specialist knowledge, analysis, experience and network of contacts within this industry makes us uniquely placed to support your business in all aspects of deal making and strategic planning.

PharmaVentures Consultancy is a leading specialist life sciences business advisory group assisting corporations in all aspects of deal transactions, from strategy formulations to implementation. We occupy a special position among advisors because of our strong analytical capabilities, proprietary deal making database and associated information assets, expertise in strategy formulation and extensive experience in deal transactions. Find out more www.pharmaventures.com/consult

Marketing and Communications Agent

De Facto Communications
De Facto Communications is the consultancy that life science and healthcare companies choose when they are looking for the best in strategic communications. As part of the Bell Pottinger Group, the UK’s largest communications services group, we offer large consultancy reach and real international influence. We’re specialists in life science and healthcare communications, clinical trial marketing and medical education, with an in-depth knowledge of the industry issues affecting your business. Based in London, we operate internationally through our Group offices in Europe and the US to reach the people you really need to influence. Contact us now for an insightful discussion about your communications needs.

Project Partners

bioProcess UK

BioSpectrumAsia

Drug Discovery Today

European Biotech News

London Biotechnology Network

Pharmalicensing
Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing provides partnering services, business development reports, industry news and a jobs source for candidates and employers.
Pharmalicensing is used by over 90,000 users per month and is a division of UTEK Corporation.

Thames Valley Life Sciences Network

Become a BioTrinity 2009 Project Partner

Media Sponsor : PharmaVentures Ltd

Marketing and Communications Agent: De Facto Communications

Project Partners
Stimutran-SME
DiagnOx
Kent Bioscience Network
South East Medical Device Network (SEMDN)
Surrey Enterprise Hub
Thames Valley Life Sciences Network (TVLSN)

Supporting Partners
Biocentury
Drug Discovery Today
European Biotechnology News

Submit your email address to receive conference updates

PROJECT PARTNERS